search

30 Facts About Sana Stock

Maggi Rusch

Written by Maggi Rusch

Published: 11 Jan 2025

Expert Verified Editorial Guidelines
30-facts-about-sana-stock
Source: Coinunited.io

Is Sana Biotechnology Stock a Good Investment? Sana Biotechnology, Inc. (NASDAQ: SANA) is a biotech company making waves with its engineered cell therapies. Founded in 2018, Sana aims to tackle diseases like cancer, diabetes, and autoimmune disorders. Despite being in early development stages, the company has a promising product pipeline, including SC291 for hematologic malignancies and ARDENT for non-Hodgkin’s lymphoma. With a market cap of around $381.79 million, Sana has caught the eye of investors. However, it reported a net loss of $305.81 million over the last year. Analysts rate it a "Strong Buy," forecasting a potential 597% increase in stock price.

Key Takeaways:

  • Sana Biotechnology is a promising company focusing on innovative cell therapies for diseases like cancer and diabetes. However, it faces financial challenges that investors should consider before investing in SANA stock.
  • SANA stock shows potential for significant growth, but its financial health and volatility should be carefully evaluated by investors. The company's focus on engineered cell therapies and diverse product pipeline are key strengths.
Table of Contents
01Company Overview
02Product Pipeline
03Financial Health
04Stock Performance
05Analyst Forecast
06Recent News and Updates
07Operational Insights
08Financial Metrics
09Company Details
10Sana Stock: A Glimpse into the Future

Company Overview

Sana Biotechnology, Inc. (NASDAQ: SANA) is a biotech company focused on engineered cell therapies. Founded in 2018, it aims to develop treatments for diseases like cancer, diabetes, and autoimmune disorders.

  1. Sana Biotechnology uses engineered cells as medicines, developing both ex vivo and in vivo cell engineering platforms.
  2. Founded in 2018, the company has quickly made strides in the biotech field.
  3. Headquartered in Seattle, Washington, Sana is strategically positioned in a biotech hub.

Product Pipeline

Sana's product pipeline is diverse, targeting multiple therapeutic areas with unmet needs.

  1. SC291 is an allogeneic cell therapy aimed at treating hematologic malignancies.
  2. ARDENT is being developed as a potential treatment for non-Hodgkin’s lymphoma and chronic lymphoblastic leukemia.
  3. GLEAM targets multiple autoimmune disorders, showcasing Sana's broad therapeutic ambitions.

Financial Health

Understanding Sana's financial health is crucial for potential investors.

  1. Market Capitalization stands at approximately $381.79 million, reflecting investor confidence.
  2. Snowflake Score of 4/6 indicates some financial strengths but also significant challenges.
  3. Net Loss of $305.81 million for the trailing twelve months (TTM) highlights the early-stage nature of the company.
  4. Revenue is currently zero, as the company is still in the development phase.
  5. Earnings per Share (EPS) is -$1.37, indicating a significant loss per share.

Stock Performance

Sana's stock performance has been volatile, reflecting the high-risk, high-reward nature of biotech investments.

  1. 52-Week High for SANA stock was $12.00.
  2. 52-Week Low was $1.52, showing significant price fluctuation.
  3. Current Share Price is $1.75, near its 52-week low.
  4. Beta of 1.45 indicates higher volatility compared to the overall market.
  5. Weekly Volatility is 12.3%, higher than 75% of US stocks but stable over the past year.

Analyst Forecast

Analysts have high hopes for Sana, despite its current financial challenges.

  1. Analyst Rating is "Strong Buy" according to three analysts.
  2. 12-Month Stock Price Forecast is $11.50, representing a potential increase of 596.97% from the latest price.
  3. Price Target of $11.50 suggests significant growth potential.

Recent News and Updates

Sana has been active in the news, making strides in various areas.

  1. Focus on Type 1 Diabetes and B-cell mediated autoimmune diseases could deliver clinical proof of concept data in 2024 and 2025.
  2. Advancing Hypoimmune Technology in three trials across five indications, including type 1 diabetes, autoimmune diseases, and oncology.

Operational Insights

Operational details provide a deeper understanding of Sana's current state.

  1. Manufacturing Facility in Fremont, California, has seen decreased costs, contributing to the net loss.
  2. Legal and Consulting Fees have decreased, impacting the net loss.
  3. Personnel-Related Costs are lower due to a decrease in headcount.
  4. Non-Cash Stock-Based Compensation has increased, partially offsetting other cost decreases.

Financial Metrics

Key financial metrics offer a snapshot of Sana's financial health.

  1. Net Loss for the three and nine months ended September 30, 2024, was $59.9 million and $217.7 million, respectively.
  2. Non-GAAP Operating Cash Burn for the nine months ended September 30, 2024, was $153.1 million, down from $187.2 million for the same period in 2023.

Company Details

Some additional details about Sana provide a fuller picture.

  1. Next Earnings Date is February 27, 2025.
  2. Employee Count stands at 328, reflecting a lean but focused team.
  3. CEO Steve Harr leads the company, guiding its strategic direction.

Sana Biotechnology is a company with a promising future in the biotech industry. Its focus on engineered cell therapies and innovative product pipeline positions it well to address significant unmet medical needs. However, the company currently faces financial challenges, which need to be addressed to achieve long-term success. Investors should carefully consider these factors when evaluating SANA stock.

Sana Stock: A Glimpse into the Future

Sana Biotechnology is making waves in the biotech world with its innovative cell therapies. Despite facing financial hurdles, the company’s product pipeline shows promise. With a market cap of around $381.79 million and a current share price of $1.75, there's significant room for growth. Analysts rate it a "Strong Buy," forecasting a potential rise to $11.50. The focus on diseases like oncology, diabetes, and autoimmune disorders highlights its commitment to addressing unmet medical needs. While the company reported a net loss of $305.81 million, its future prospects look bright with upcoming clinical trials and advancements in hypoimmune technology. Investors should keep an eye on Sana's progress, as its innovative approach could lead to groundbreaking treatments and substantial returns.

Frequently Asked Questions

What exactly is Sana Stock?
Sana Stock refers to shares of Sana Biotechnology, Inc., a company focused on engineering cells to create a new generation of therapies for various diseases. They're at the forefront of biotech innovation, aiming to solve some of the most complex challenges in medicine.
How can someone invest in Sana Stock?
Investing in Sana Stock involves buying shares through a brokerage account. First, you'll need to set up an account with a broker that offers access to the NASDAQ, where Sana's shares are traded. Once your account is set up and funded, you can search for Sana Biotechnology using its ticker symbol and proceed to buy shares.
Why has Sana Stock been in the news recently?
Sana Stock has grabbed headlines due to its groundbreaking work in cell therapy and regenerative medicine. Their innovative approaches to treating diseases that currently have limited treatment options have sparked interest among investors and the medical community alike.
What risks are associated with investing in Sana Stock?
Like any investment, Sana Stock comes with its share of risks. These include the volatile nature of biotech stocks, regulatory hurdles, and the company's need to continually fund research and development. Potential investors should do their homework and consider these factors carefully.
Can Sana Stock be considered a good long-term investment?
Whether Sana Stock is a good long-term investment depends on several factors, including the company's ability to bring its therapies to market, regulatory approvals, and its financial health. While the biotech sector offers significant growth potential, it's also fraught with uncertainty. Investors should weigh these aspects and their own risk tolerance.
How does Sana Biotechnology stand out in the biotech industry?
Sana Biotechnology stands out due to its focus on creating engineered cells as medicines, which represents a cutting-edge approach in the field. Their commitment to tackling hard-to-treat diseases and the expertise of their team have positioned them as leaders in cell therapy and regenerative medicine.
What should potential investors watch for in Sana's future announcements?
Potential investors should keep an eye out for updates on clinical trials, partnerships, and regulatory milestones. Success in these areas can significantly impact the company's stock price and its prospects for long-term success. Additionally, financial performance and research breakthroughs are key indicators to watch.

Was this page helpful?

Our commitment to delivering trustworthy and engaging content is at the heart of what we do. Each fact on our site is contributed by real users like you, bringing a wealth of diverse insights and information. To ensure the highest standards of accuracy and reliability, our dedicated editors meticulously review each submission. This process guarantees that the facts we share are not only fascinating but also credible. Trust in our commitment to quality and authenticity as you explore and learn with us.